A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

Inclusion Criteria Subjects must have: * Normal history and physical exam. * Negative for HIV infection by ELISA and Western blot (i.e., no reactivity at gp160, gp120, gp41, or p24). * T4 count \>= 800 cells/mm3. * Normal chest x-ray and urinalysis. * Negative surface antibody and core antibody for hepatitis B. * Negative hepatitis B surface antigen. * Negative HIV p24 antigen test. * Normal skin reactivity by Merieux test. Exclusion Criteria Co-existing Condition: Subjects with the following symptoms or conditions are excluded: * Positive PPD. * Syphilis, gonorrhea, or any other sexually transmitted diseases (including chlamydia or pelvic inflammatory disease). Subjects with the following prior conditions are excluded: * History of immunodeficiency, chronic illness, or use of immunosuppressive medications. * Prior hepatitis B vaccination. * Syphilis, gonorrhea, or any other sexually transmitted diseases (including chlamydia or pelvic inflammatory disease) in the past 6 months. Prior Medication: Excluded: * Prior hepatitis B vaccine. Prior Treatment: Excluded: * Prior blood transfusions or cryoprecipitates within the past 6 months. Identifiable high-risk behavior for HIV infection (as determined by prescreening questions designed to identify risk factors for HIV infection), including: * Any history of IV drug use. * Syphilis, gonorrhea, or any other sexually transmitted diseases (including chlamydia or pelvic inflammatory disease) in the past 6 months. * More than two sexual partners, or sexual contact with a high-risk partner, in the past 6 months.